Alphatec director Evan Bakst acquires $203k worth of shares
© Reuters.
Alphatec Holdings , Inc. (NASDAQ:), a company specializing in surgical and medical instruments, has seen a recent purchase of shares by one of its directors. Evan Bakst, a director at Alphatec, acquired 15,000 shares of common stock at a weighted average price of $13.53 per share, amounting to a total investment of $202,950.
The transaction, which took place on March 14, 2024, was executed in multiple transactions with prices ranging from $13.50 to $13.55, inclusive. This purchase has increased Bakst’s direct holdings in the company, which now total 1,089,038 shares of Alphatec’s common stock.
Shareholders and potential investors often keep a close eye on insider transactions as they can provide insights into how the company’s leadership views the stock’s value and prospects. The recent acquisition by Bakst might be interpreted as a sign of confidence in the future of Alphatec Holdings.
Alphatec Holdings, Inc. is incorporated in Delaware and has its business address in Carlsbad, California. The company continues to focus on the development and marketing of products for the surgical and medical apparatus sector.
Investors interested in the specifics of the transactions can request more detailed information regarding the number of shares purchased at each separate price within the reported range.
InvestingPro Insights
As investors digest the news of Director Evan Bakst’s recent purchase of Alphatec Holdings, Inc. (NASDAQ:ATEC) shares, it’s important to look at the broader financial context provided by InvestingPro. The company’s market capitalization stands at $1.86 billion, reflecting its size and market value within the surgical and medical instruments sector. Despite a strong revenue growth of 37.45% over the last twelve months as of Q4 2023, Alphatec’s performance indicators suggest some challenges. Notably, the company is currently trading at a high Price / Book multiple of 23.77, which could signal that the stock is quite expensive relative to the company’s book value.
From a profitability standpoint, Alphatec has not been profitable over the last twelve months, with an adjusted P/E Ratio of -11.25, indicating that the company has been operating at a loss. This aligns with an InvestingPro Tip that analysts do not anticipate the company will be profitable this year. Additionally, the stock has experienced significant volatility, with a 1-month price total return of -15.66%. This could be an important consideration for investors looking for stable returns.
However, there are positive signals as well. Alphatec’s liquid assets exceed its short-term obligations, which suggests the company has a solid liquidity position to meet its immediate financial needs. This is a reassuring sign for investors concerned about the company’s financial health in the short term.
To gain a fuller understanding of Alphatec’s financial health and future prospects, investors can explore additional InvestingPro Tips. There are currently 9 more tips available, which can be accessed by visiting InvestingPro. Use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and uncover even more insights that could guide your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
